Search

Displaying results 951 - 960 of 3735 in total
  1. Drug

    Human Rho(D) immune globulin

    go.drugbank.com/drugs/DB11597
    Approved

    Immune globullin was purified via ion-exchange chromatography method and prepared from pools of human plasma, where the donors are Rho (D)-negative donors who have been immunized with Rho(D)-positive RBCs

  2. Drug

    Eucalyptus oil

    go.drugbank.com/drugs/DB11114
    Approved

    It is shown to be effective in reducing pain, swelling, and inflammation via its modulatory effect on the immune response.

    Mixtures: Vaporizing Chest Rub 4 oz. 3 pk
  3. Target

    Cytochrome c oxidase subunit 7A1, mitochondrial

    go.drugbank.com/bio_entities/BE0003996
    TargetHumans

    Component of the mitochondrial respiratory complex IV (CIV, also named cytochrome c oxidase complex), the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation (By similarity). The CIV complex i...

    Synonyms: Cytochrome c oxidase subunit VIIa-H, Cytochrome c oxidase subunit VIIa-M
  4. Drug

    PG-530742

    go.drugbank.com/drugs/DB05495
    Investigational

    Studies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis. … PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis.

  5. Drug

    Gavorestat

    go.drugbank.com/drugs/DB16707
    Investigational

    Gavorestat is under investigation in clinical trial NCT04902781 (Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia).

  6. Drug

    Etravirine

    go.drugbank.com/drugs/DB06414
    ApprovedInvestigational

    Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1), and consequently blocks DNA-dependent and RNA-dependent polymerase

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  7. Drug

    IONIS-FGFR4Rx

    go.drugbank.com/drugs/DB16198
    Investigational

    IONIS-FGFR4Rx is under investigation in clinical trial NCT02476019 (A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients).

  8. Drug

    Ciclesonide

    go.drugbank.com/drugs/DB01410
    ApprovedInvestigational

    Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    It is injected once every four weeks via intravenous infusion. Cinqair is indicated as an add-on maintenance therapy for adults with severe asthma with an eosinophilic phenotype.

  10. Target

    G protein-coupled receptor kinase 2

    go.drugbank.com/bio_entities/BE0000341
    TargetHumans

    Such receptor phosphorylation initiates beta-arrestin-mediated receptor internalization, and signaling events leading to their desensitization (PubMed:14976224, PubMed:16179383, PubMed:19306925, PubMed … Also able to mediate phosphorylation-independent desensitization of dopamine receptor DRD2 (By similarity)

    Polypeptides: G protein-coupled receptor kinase 2Synonyms: Beta-adrenergic receptor kinase 1